{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T10:27:53Z","timestamp":1779272873784,"version":"3.51.4"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Pneumonitis is a well-described, potentially life-threatening adverse effect of immune checkpoint inhibitors (ICI) and thoracic radiotherapy. It can require additional investigations, treatment, and interruption of cancer therapy. It is important for clinicians to have an awareness of its incidence and severity, however real-world data are lacking and do not always correlate with findings from clinical trials. Similarly, there is a dearth of information on cost impact of symptomatic pneumonitis. Informatics approaches are increasingly being applied to healthcare data for their ability to identify specific patient cohorts efficiently, at scale. We developed a Structured Query Language (SQL)-based informatics algorithm which we applied to CT report text to identify cases of ICI and radiotherapy pneumonitis between 1\/1\/2015 and 31\/12\/2020. Further data on severity, investigations, medical management were also acquired from the electronic health record. We identified 248 cases of pneumonitis attributable to ICI and\/or radiotherapy, of which 139 were symptomatic with CTCAE severity grade 2 or more. The grade \u22652 ICI pneumonitis incidence in our cohort is 5.43%, greater than the all-grade 1.3\u20132.7% incidence reported in the literature. Time to onset of ICI pneumonitis was also longer in our cohort (mean 4.5 months, range 4 days-21 months), compared to the median 2.7 months (range 9 days\u221219.2 months) described in the literature. The estimated average healthcare cost of symptomatic pneumonitis is \u00a33932.33 per patient. In this study we use an informatics approach to present new real-world data on the incidence, severity, management, and resource burden of ICI and radiotherapy pneumonitis. To our knowledge, this is the first study to look at real-world incidence and healthcare resource utilisation at the per-patient level in a UK cancer hospital. Improved management of pneumonitis may facilitate prompt continuation of cancer therapy, and improved outcomes for this not insubstantial cohort of patients.<\/jats:p>","DOI":"10.3389\/fmed.2021.764563","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T05:21:56Z","timestamp":1635744116000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications"],"prefix":"10.3389","volume":"8","author":[{"given":"Sumeet","family":"Hindocha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Des","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merina","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyriaki","family":"Giorgakoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhupinder","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Yousaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Molyneaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hardeep","family":"Kalsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanyuan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaishree","family":"Bhosle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Minchom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imogen","family":"Locke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","article-title":"Advances in cancer immunotherapy 2019 - latest trends","volume":"38","author":"Kruger","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5306\/wjco.v8.i1.37","article-title":"From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1\/PD-L1 axis","volume":"8","author":"Bersanelli","year":"2017","journal-title":"World J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/cancers10070222","article-title":"Radiation pneumonitis: old problem, new tricks","volume":"10","author":"Jain","year":"2018","journal-title":"Cancers"},{"key":"B7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s40425-019-0583-3","article-title":"Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features","volume":"7","author":"Schoenfeld","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.jtho.2018.10.007","article-title":"Checkpoint inhibitor pneumonitis - real-world incidence and risk","volume":"13","author":"Tay","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.20982\/tqmp.08.1.p023","article-title":"Computing inter-rater reliability for observational data: an overview and tutorial. Tutor Quant Methods Psychol","volume":"8","author":"Hallgren","year":"2012","journal-title":"Quant Methods Psychol"},{"key":"B10","unstructured":"National Cost Collection for the NHS"},{"key":"B11","unstructured":""},{"key":"B12","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S2213-2600(20)30170-3","article-title":"Challenges in lung cancer therapy during the COVID-19 pandemic","volume":"8","author":"Calabr\u00f2","year":"2020","journal-title":"Lancet Respirat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1177\/0300891620951863","article-title":"Interstitial pneumonitis in the COVID-19 era: a difficult differential diagnosis in patients with lung cancer","volume":"107","author":"Catania","year":"2020","journal-title":"Tumor J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2217\/imt-2020-0067","article-title":"Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors","volume":"12","author":"Bersanelli","year":"2020","journal-title":"Immunotherapy"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.764563\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T05:21:59Z","timestamp":1635744119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.764563\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":14,"alternative-id":["10.3389\/fmed.2021.764563"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.764563","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"article-number":"764563"}}